NCT04138914Active, not recruiting
Phase II Trial of Focal Cryotherapy for Prostate Cancer
Source: ClinicalTrials.gov · Last updated 4 Apr 2023
Brief summary (registry, in English)
The current standard of care treatment for prostate cancer confined to the prostate is surgical removal or irradiation of the entire prostate gland. This is effective at curing cancer but result in damage to critical adjacent structures such as the urinary sphincter muscle and erectile nerves resulting in impaired urinary continence and erectile dysfunction. The concept of focal therapy is to treat just the dangerous focus of cancer in the prostate while monitoring the rest of the gland, thus avoiding impairment of urinary continence and erectile function. We aim to evaluate the degree of preservation of continence and erectile function and early oncological outcomes in patients undergoing focal therapy of the prostate using cold energy or cryo- ablation. In this study, we seek to evaluate patient reported outcomes in urinary, sexual, bowel and general health areas at fixed time points after focal cryo-ablation in selected patients with low-volume, localized cancer. The primary goal of this study is to demonstrate whether there is a deterioration of scores in these health areas over 1 year of follow-up. The secondary goal is to measure cancer control at 1 year re-biopsy. Further goals include longer follow-up to monitor cancer progression rates and impact on patient survival.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 23 Oct 2019
- Start date
- 1 Mar 2019
- Primary completion date
- 31 Jan 2021
- Lead sponsor
- Singapore General Hospital
- Diseases
- Prostate cancer
- NCT number
- NCT04138914
What you commit to
- Study type: Interventional
- Participants enrolled: 30
- From 1 Mar 2019 to the primary completion date, 31 Jan 2021
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Very high grade cancer (Gleason score \> 4+4)
- Multifocal cancer (any other Gleason \>3+3 present and/or Gleason 3+3 at \> 3 biopsy cores at another site) - Not eligible for mpMRI
Other
- American Society of Anesthesiologist score \>3
- \>2 index lesions
- Not fit for robotic transperineal saturation biopsy
Who the study is looking for
- PSA (prostate specific antigen) ≤ 20
- Biopsy Gleason score ≤ 4+4
- mpMRI shows no gross extracapsular extension
- mpMRI shows index lesion volume \< 3 ml
- ≤ 2 biopsy confirmed lesions on mpMRI
Age in the registry: 18 years to 80 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Singapore General Hospital Coordinator of this site? Confirm its status | Singapore | Singapore | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.